Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : recommandations par le groupe PATTERN de pathologistes thoraciques

(2018) Sylvie Lantuejoul et al.   ANNALES DE PATHOLOGIE

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

(2018) Jooeun Bae et al.   LEUKEMIA

Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages

(2018) Xiaolei Wang et al.   TUBERCULOSIS

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

(2018) Taku Fujimura et al.   Oncotarget

Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases

(2018) Pooja Dhupkar et al.   Cancer Medicine

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

(2018) Priyanka B. Subrahmanyam et al.   Journal for ImmunoTherapy of Cancer

Tumor-associated macrophages: from basic research to clinical application

(2017) Li Yang et al.   Journal of Hematology & Oncology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models

(2017) Maurício T. Tavares et al.   ACS Medicinal Chemistry Letters

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3

(2017) Lulu Ni et al.   Scientific Reports

A Breakthrough: Macrophage-Directed Cancer Immunotherapy

(2016) C. D. Mills et al.   CANCER RESEARCH

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma

(2016) Nghia Nguyen et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Essential role of HDAC6 in the regulation of PD-L1 in melanoma

(2016) M. Lienlaf et al.   Molecular Oncology

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

(2016) Pengyu Huang et al.   Oncotarget

Huaier extract suppresses breast cancer via regulating tumor-associated macrophages

(2016) Yaming Li et al.   Scientific Reports

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

(2016) Theodore S. Nowicki et al.   Cancer Immunology Research

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages

(2016) Bisweswar Nandi et al.   OncoImmunology

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

(2015) K.V. Woan et al.   Molecular Oncology

PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition

(2015) Z Meng et al.   ONCOGENE

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer

(2015) Christine Pasero et al.   Oncotarget

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

(2015) Blanca Homet Moreno et al.   OncoImmunology

A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs

(2014) Fengdong Cheng et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression

(2014) Caroline Aspord et al.   OncoImmunology

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity

(2013) Gang Ding et al.   FEBS LETTERS

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration

(2013) Kendra A. Williams et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

(2013) Maria Ascierto et al.   Journal of Translational Medicine

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

(2013) David M. Woods et al.   MELANOMA RESEARCH

HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS

(2013) M. H. Yang et al.   MOLECULAR CANCER RESEARCH

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression

(2011) Rui Wang et al.   LUNG CANCER

The Role of HDAC6 in Cancer

(2010) Grace I. Aldana-Masangkay et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone deacetylases and the immunological network: implications in cancer and inflammation

(2009) A Villagra et al.   ONCOGENE

The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance

(2008) Paola Allavena et al.   IMMUNOLOGICAL REVIEWS

Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

(2008) Y. Zhang et al.   MOLECULAR AND CELLULAR BIOLOGY